Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)-Reference-Cited by-同舟云学术

Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)

Published:2021-05 Issue:5 Volume:84 Page:1269-1277
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Lebwohl Mark,Kircik Leon,Lacour Jean-Philippe,Liljedahl Monika,Lynde Charles,Mørch Marie Holst,Papp Kim A.,Perrot Jean-Luc,Gold Linda Stein,Takhar Amrit,Thaçi Diamant,Warren Richard B.,Wollenberg Andreas

Funder

LEO Pharma

Ballerup

Denmark

Manchester National Institute for Health Research

Biomedical Research Centre

AbbVie Inc

Amgen

Arcutis Biotherapeutics

Boehringer Ingelheim

Dermavant Sciences Ltd

Eli Lilly and Company

Incyte

Janssen Research & Development

LLC

Ortho Dermatologics

Pfizer

UCB, Inc

Bristol-Myers Squibb

Celgene

Dermira

Galderma

Janssen Pharmaceuticals

Merck

Novartis

Regeneron Pharmaceuticals

Roche

Actelion

Allergan

Anacor Pharmaceuticals Inc

Astellas Pharma

Avillion

Bausch Health

EMD Serono

Gilead

GlaxoSmithKline

Incyte Corporation

Kyowa Kirin

Meiji Seika

Sanofi Genzyme

Takeda Pharmaceutical Company

UCB Pharma

Abbott

Janssen-Cilag Ltd

Johnson & Johnson

Merck Serono

Merck Sharp & Dohme

Pierre Fabre

Sanofi-Aventis

Schering-Plough

AstraZeneca

Bayer

Cambridge and Peterborough Clinical Commissioning Group

Daiichi Sankyo

Dermal Laboratories

Sanofi

; Author Takhar has received grants/research support from National Institute of Health Research UK

Almirall

Asana

Bioskin

Biogen

DS Biopharma

Galapagos NV

Kymab

MorphoSys AG

Sandoz

Samsung

Sharp & Dohme Corp

UCB

Beiersdorf

Bioderma

Chugai Pharmaceutical Co

Hans Karrer

L'Oréal, Maruho Co, Ltd

MedImmune

Santen

Publisher

Elsevier BV

Subject

Dermatology

Reference18 articles.

1. Pathogenesis and clinical features of psoriasis;Griffiths;Lancet,2007

2. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an eight-year multicenter study;Chiu;J Am Acad Dermatol,2019

3. Treatment approaches to moderate to severe psoriasis;Gisondi;Int J Mol Sci,2017

4. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives;Feldman;Am Health Drugs Benefits,2016

5. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011;Armstrong;JAMA Dermatol,2013

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature;Dermatology and Therapy;2023-09-22

2. Topical foam as a promising carrier system for active pharmaceutical ingredients: review of clinical studies;Pharmaceutical Development and Technology;2023-08-26

3. Real‐world efficacy of adjunctive calcipotriene/betamethasone dipropionate foam for recalcitrant psoriatic lesions on the scalp or lower legs with biologic therapy;The Journal of Dermatology;2023-06-22

4. Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness;Journal of Dermatological Treatment;2023-04-20

5. Relationship between genetically proxied vitamin D and psoriasis risk: a Mendelian randomization study;Clinical and Experimental Dermatology;2023-03-11